Document:

Exhibit 10.1

 

CANNABICS PHARMACEUTICALS INC.

CONSULTING AGREEMENT

 

THIS AGREEMENT is among
CANNABICS PHARMACEUTICALS INC. a corporation organized under laws of the State of Nevada, whose address is #3 Bethesda Metro
Center, Suite 700, Bethesda, Maryland 20814 (hereinafter referred to as the "Company"); and WEINBERG DALYO INC.,
an New York Corporation in good standing with an address of 21 Sparrow Circle, White Plains, New York 10605 (hereinafter referred
to as the "Consultant").

 

WHEREAS, the
Consultant is a Certified Public Accountant with over 30 years executive Corporate experience in corporate finance and in the
Bio-tech, life science and medical device industries and adept at assisting businesses in financial advisory,
strategic business planning;

 

WHEREAS, the Consultant
may, during the period of time covered by this Agreement, present to the Company one or more plans to aid the Company in achieving
the Company's goals; and

 

WHEREAS, the Company recognizes
that the Consultant is not in a position which requires registration under either the Securities Act of 1933 (hereinafter "the
Act") or the Securities and Exchange Act of 1934 (hereinafter "the Exchange Act"), underwriting, banking, is not
an insurance Company, nor does it offer services to the Company which may require regulation under federal or state securities
laws or licensing in the state of Israel; and

 

WHEREAS, the parties agree,
after having a complete understanding of the services desired and the services to be provided, that the Company desires to retain
Consultant to provide such assistance through its services for the Company, and the Consultant is willing to provide such services
to the Company; and in light of his qualifications, to be its Chief Financial Officer (“CFO”).

 

NOW, THEREFORE, in consideration
of the mutual covenants and promises contained herein, the receipt and sufficiency of which is hereby acknowledged, the parties
agree as follows:

 

1. DUTIES AND INVOLVEMENT.

 

The Company hereby engages
Consultant for coordination in executing an agreed-upon plan, for aiding the company by his knowledge and experience as agreed
by both parties.

 

2. RELATIONSHIP AMONG THE PARTIES.

 

Consultant acknowledges
that as CFO he is not, and will not, be responsible for any management decisions on behalf of the Company, and may not at any time
commit the Company to any action. The Company represents that the consultant does not have, through any means the power to control
the Company, nor to exercise any dominating influences over its management.

 

Consultant understands
and acknowledges that this Agreement shall not create or imply any agency relationship among the parties, and Consultant shall
have no authority to enter into any contracts or otherwise legally bind the Company.

    	1

    	 

    

Consultant’s relationship with the Company
shall be that of an independent contractor and not an employee. Consultant shall not be eligible for any employee benefits, nor
is the Company liable to make deductions from consideration paid to Consultant for taxes, all of which will be Consultant’s
responsibility.

 

3. EFFECTIVE DATE, TERM
AND TERMINATION.

 

This Agreement shall be
effective on 15th day of March, 2015 and will continue until 15th September, 2015. This Six Month Agreement
can only be modified if mutually agreeable and in writing.

 

4. OPTION TO RENEW AND
EXTEND.

 

Company may renew this
Agreement on the same terms by providing written notice to Consultant at any time prior to the expiration hereof.

 

5. COMPENSATION AND PAYMENT OF EXPENSES

 

The Consultant shall be
paid $4,000- monthly. In the event the company is undergoing a limited cash flow, the Consultant shall in no event receive less
than $1,000 per month, the balance ($3,000-) to be paid in common shares of the Company. In appreciation and recognition of the
Consultant’s belief and faith in the Company, the Company shall issue 90,000 shares of the company upon signing, which amount
represents the underage of $3,000 per month over the course of this contract. If and when the Company is sufficiently funded to
enable the full monthly retainer of $4,000- prior to the expiration of this Contract, this full allotment of shares is to remain
with the Consultant as a token of gratitude. The monthly invoice for the cash portion of this agreement will be issued to the company
by the consultant on a monthly basis for the previous month. Payment will be made via a wire transfer within 5 days of the receipt
of the invoice.

 

The Shares of Common Stock to be issued to
Consultant shall be duly authorized and validly issued, fully paid and no assessable, free of liens, encumbrances and restrictions
on transfer, and shall be issued in accordance with the registration or qualification provisions of the Securities Act of 1933,
as amended, and any relevant securities laws or pursuant to valid exemptions there from.

 

The Company’s Board
of Directors has authorized the issuance of the Shares set forth in this Section for consideration consisting of this Agreement
and the Services to be provided hereunder. The Company’s Board of Directors has determined that the consideration received
for the Shares, consisting of this Agreement and the Services to be provided hereunder, is adequate. In rendering its Services,
Consultant will be using and relying on the information supplied to it by the Company. The Company hereby represents that all information
made available to Consultant by the Company will be complete and correct in all material respects and will not contain any untrue
statement of material fact.

    	2

    	 

    

 

The Company agrees to pay for reasonable expenses,
including lodging, meals, and travel as necessary. All other expenses for the fulfillment of this Agreement shall be borne by the
Consultant, and by third parties engaged by it in connection with the performance services provided for herein, after approval
from the Company.

 

6. SERVICES NOT
EXCLUSIVE.

 

Consultant shall devote
such of its time and effort necessary to the discharge of its duties hereunder. The Company acknowledges that Consultant is engaged
in other business activities, and that it will continue such activities during the term of this Agreement. Consultant shall not
be restricted from engaging in other business activities during the term of this Agreement.

 

7.
CONFIDENTIALITY, NON-DISCLOSURE, NON-CIRCUMVENTION, NON-COMPETE 

 

Consultant acknowledges that it may have access
to confidential information regarding the Company and its business. Consultant agrees that it will not, during or subsequent to
the term of this Agreement, divulge, furnish or make accessible to any person (other than with the written permission of the Company)
any knowledge or information or plans of the Company with respect to the Company or its business, including, but not by way of
limitation, the products of the Company, whether in the concept or development stage, or being marketed by the Company on the effective
date of this Agreement or during the term hereof.

 

a) Therefore, the parties
mutually recognize that in the transaction of their affairs each may learn from the other, including associates, the identity,
address and/or telephone and/or telefax and/or E-mail address and/or number of clients, agents, brokers, buyers, sellers, financiers
and/or bank or trust contracts (hereinafter referred to as “Confidential Sources”) which the other party has acquired
by periods of investment in time, expense and effort. Now therefore consideration of the mutual promises set forth herein, each
party covenants and agrees with the other as follows:

 

The parties hereto hereby contractually covenant,
warrant, guarantee and agree as follows: to irrevocably mutually covenant, as evidenced and acknowledged by this memorization of
their executions hereof, agree as follows:

 

b) Each of the signatories to the within
contractual Agreement and their employees, agents, associates, and/or any other parties with whom they maintain a corporate or
individual relationship, or who they may act as agents or principals for, shall be deemed to be parties to the within Confidentiality,
Non-Circumvention, Non-Disclosure, Non-Compete, Agreement and shall be contractually bound to full compliance with the letter,
spirit and intent of the within Agreement, and shall be fully bound by each and all of the terms, covenants and conditions of this
Agreement. All documents signed on behalf of a corporation shall be deemed to be executed with full authority of the Board of Directors.

 

c) The within Agreement is executed and affected
by the parties as a perpetuating guarantee and contractual agreement by the parties. Therefore, this Agreement
shall be in full force and effect commencing the date affixed herein below and will during said term be applicable to any and all
potential transactions and/or proprietary information transmitted to or entertained by the undersigned parties hereto. 

    	3

    	 

    

 

d) The parties hereto covenant, warrant and
agree not to circumvent the interests, intentions, plans, and proposed undertakings of the party of the other part or to enter
upon a competitive path and/or effort, or to utilize any of the proprietary information delivered into its custody, care and control
or that would in any fashion interfere with, conflict with, or diminish, the possibility and/or probabilities of its success in
any ventures, projects, proposed acquisitions, financial undertakings, and/or other activities which this office shall be a party
to.

 

8. MISCELLANEOUS
PROVISIONS

 

Section a Time. Time is of the essence of this
Agreement.

 

Section b Presumption. This Agreement or any
section thereof shall not be construed against any party due to the fact that said Agreement or any section thereof was drafted
by said party.

 

Section c Computation of Time. In computing
any period of time pursuant to this Agreement, the day of the act, event or default from which the designated period of time begins
to run shall be included, unless it is Shabbat, a Jewish or a legal US holiday, in which event the period shall begin to run on
the next day which is not Shabbat, a Jewish or legal US holiday, in which event the periods shall run until the end of the next
day thereafter.

 

Section d Titles and Captions. All article,
section and paragraph titles or captions contained in this Agreement are for convenience only and shall not be deemed part of the
context nor affect the interpretation of this Agreement.

 

Section e Pronouns and Plurals. All pronouns
and any variations thereof shall be deemed to refer to the masculine, feminine, neuter, singular or plural as the identity of the
Person or Persons may require.

 

Section f Further Action. The parties hereto
shall execute and deliver all documents, provide all information and take or forbear from all such action as may be necessary or
appropriate to achieve the purposes of this Agreement.

 

Section g Good Faith, Cooperation and Due Diligence.
The parties here to covenant, warrant and represent to each other good faith, complete cooperation, due diligence and honesty in
fact in the performance of all obligations of the parties pursuant to this Agreement. All promises and covenants are mutual and
dependent

 

Section h Savings Clause. If any provision
of this Agreement, or the application of such provision to any person or circumstance, shall be held invalid, the remainder of
this Agreement, or the application of such provision to persons or circumstances other than those as to which it is held invalid,
shall not be affected thereby.

 

Section i Assignment. This Agreement may not
be assigned by either party hereto without the written consent of the other, but shall be binding upon the successors of the parties.

    	4

    	 

    

 

Section j Arbitration. In the event of any
controversy among the parties hereto arising out of, or relating to, this Agreement, which cannot be settled amicably by the parties,
such controversy shall be settled by Arbitration. Both sides shall choose a mutually agreed upon competent jurist from a short
list and informal Arbitration shall commence as expeditiously as possible. Either party may institute such arbitration proceeding
by giving written notice to the other party. A hearing shall be held by the Arbitrator within the District of Columbia, and a decision
of the matter submitted to the Arbitrator shall be biding and enforceable against all parties in any Court of competent jurisdiction.
The prevailing party shall be entitled to all costs and expenses with respect to such arbitration, including reasonable attorneys'
fees. The decision of the Arbitrator shall be final, binding upon all parties hereto and enforceable in any Court of competent
jurisdiction. Each party hereto irrevocably waives any objection to the laying of venue of any such Arbitration action or proceeding
brought and irrevocably waives any claim that any such action brought has been brought in an inconvenient forum. Each of the parties
hereto waives any right to request a trial by jury in any litigation with respect to this agreement and represents that counsel
has been consulted specifically as to this waiver.

 

Section k Notices. All notices required or
permitted to be given under this Agreement shall be given in writing and shall be delivered, either personally or by express delivery
service, to the party to be notified. Notice to each party shall be deemed to have been duly given upon delivery, personally or
by courier (such as Federal Express or similar express delivery service), addressed to the attention of the officer at the address
set forth heretofore, or to such other officer or addresses as either party may designate, upon at least ten (10) days' written
notice, to the other party.

 

Section l Governing law. The Agreement shall
be construed by and enforced in accordance with the laws of the State of Maryland, USA.

 

Section m Entire agreement. This Agreement
contains the entire understanding and agreement among the parties. There are no other agreements, conditions or representations,
oral or written, express or implied, with regard thereto. This Agreement may be amended only in writing signed by all parties.

 

Section n Waiver. A delay or failure by any
party to exercise a right under this Agreement, or a partial or single exercise of that right, shall not constitute a waiver of
that or any other right.

 

Section o Counterparts. This Agreement may
be executed in duplicate counterparts, each of which shall be deemed an original, but all of which together shall constitute one
and the same Agreement. In the event that the document is signed by one party and faxed to another the parties agree that a faxed
signature shall be binding upon the parties to this agreement as though the signature was an original.

 

Section p Successors. The provisions of this
Agreement shall be binding upon all parties, their successors and assigns.

 

Section q Counsel. The parties expressly acknowledge
that each has been advised to seek separate counsel for advice in this matter and has been given a reasonable opportunity to do
so.

    	5

    	 

    

 

IN WITNESS WHEREOF, the
parties hereto have executed and delivered this Agreement to be effective as of the date first referenced above.

 

 

COMPANY

 

/s/ Itamar Borochov

Itamar Borochov, Dir., on behalf of Cannabics
Pharmaceuticals Inc.

 

 

 

CONSULTANT:

 

/s/ Dov Weinberg

Dov Weinberg, Dir., on behalf of WEINBERG
DALYO INC.

 

    	6Exhibit 10.1

 

EXECUTIVE EMPLOYMENT AGREEMENT

 

This Employment Agreement
(the “Agreement”), made and entered into this 6th day of April, 2015 (the “Effective Date”),
by and between Interleukin Genetics, Inc, a Delaware corporation (“Company”), and Mark Carbeau (“Executive”).

 

WHEREAS, Company
wishes to employ Executive as its Chief Executive Officer;

 

WHEREAS, Executive
represents that Executive possesses the necessary skills to perform the duties of this position and that Executive has no obligation
to any other person or entity which would prevent, limit or interfere with Executive’s ability to do so;

 

WHEREAS, Executive
and Company desire to enter into a formal Employment Agreement to assure the harmonious performance of the affairs of Company.

 

NOW, THEREFORE,
in consideration of the mutual promises, terms, provisions, and conditions contained herein, the parties agree as follows:

 

1.                 
Roles and Duties. 

 

(a)               
Chief Executive Officer Role. Subject to the terms and conditions of this Agreement, Company shall employ
Executive as its Chief Executive Officer (“CEO”) reporting to Company’s Board of Directors (“Board”).
Executive accepts such employment upon the terms and conditions set forth herein, and agrees to perform to the best of Executive’s
ability the duties normally associated with such position and as determined by Company in its sole discretion. During Executive’s
employment, Executive shall devote substantially all of Executive’s business time and energies to the business and affairs
of Company, provided that nothing contained in this Section 1 shall prevent or limit Executive’s right to manage Executive’s
personal investments on Executive’s own personal time, including, without limitation the right to make passive investments
in the securities of: (a) any entity which Executive does not control, directly or indirectly, and which does not compete with
Company, or (b) any publicly held entity so long as Executive’s aggregate direct and indirect interest does not exceed two
percent (2%) of the issued and outstanding securities of any class of securities of such publicly held entity. During Executive’s
employment, Executive shall not engage in any other non-Company related business activities of any nature whatsoever (including
board memberships) without Company’s prior written consent, which consent shall not be unreasonably withheld, provided
that Company consents to Executive serving as a member of the Board of Directors or Advisory Council Boards for the entity/ies
listed in Exhibit A. In addition, and so long as such activities do not interfere with Executive’s performance of
Executive’s duties hereunder (including Executive’s full devotion of business time and energies to the business and
affairs of Company, as described above), Executive also may participate in civic, charitable and professional activities, but shall
not serve in any official capacity, including as a member of a board, without the prior written approval of the Board.

 

(b)               
Board Membership.
Executive shall serve as a member of the Board during Executive’s employment hereunder, subject to any required approval.
Executive’s service as a Board member shall be without further compensation. Executive shall resign from the Board effective
immediately upon the termination of Executive’s employment with Company for any reason.

 

    	 

    	 

    

 

2.                 
Term of Employment.

 

(a)               
Term. Subject to the terms hereof, Executive’s employment hereunder shall commence on April 6, 2015
(the “Commencement Date”) and shall continue until terminated hereunder by either party (such term of employment referred
to herein as the “Term”).

 

(b)              
Termination. Notwithstanding anything else contained in this Agreement, Executive’s employment hereunder
shall terminate upon the earliest to occur of the following:

 

(i)                
Death. Immediately upon Executive’s death.

 

(ii)              
Termination by Company.

 

(A)             
If because of Executive’s Disability (as defined below in Section 2(c)), upon written notice by Company to
Executive that Executive’s employment is being terminated as a result of Executive’s Disability, which termination
shall be effective on the date of such notice or such later date as specified in writing by Company;

 

(B)             
If for Cause (as defined below in Section 2(d)), upon written notice by Company to Executive that Executive’s
employment is being terminated for Cause, which termination shall be effective on the date of such notice or such later date as
specified in writing by Company; or

 

(C)             
If by Company for reasons other than under Sections 2(b)(ii)(A) or (B), upon written notice by Company to Executive
that Executive’s employment is being terminated, which termination shall be effective thirty (30) days after the date of
such notice or such later date as specified in writing by Company.

 

(iii)            
Termination by Executive.

 

(A)             
If for Good Reason (as defined below in Section 2(e)), upon written notice by Executive to Company that Executive
is terminating Executive’s employment for Good Reason and that sets forth the factual basis supporting the alleged Good Reason,
which termination shall be effective thirty (30) days after the date of such notice; provided that if Company has cured
the circumstances giving rise to the Good Reason, then such termination shall not be effective; or

 

(B)             
If without Good Reason, written notice by Executive to Company that Executive is terminating Executive’s employment,
which termination shall be effective at least thirty (30) days after the date of such notice.

 

Notwithstanding anything
in this Section 2(b), Company may at any point terminate Executive’s employment for Cause prior to the effective date of
any other termination contemplated hereunder.

 

(c)               
Definition of “Disability”. For purposes of this Agreement, “Disability” shall mean
Executive’s incapacity or inability to perform Executive’s duties and responsibilities as contemplated herein for one
hundred twenty (120) days or more within any one (1) year period (cumulative or consecutive), because Executive’s physical
or mental health has become so impaired as to make it impossible or impractical for Executive to perform the duties and responsibilities
contemplated hereunder. Determination of Executive’s physical or mental health shall be made by Company after consultation
with a medical expert appointed by mutual agreement between Company and Executive who has examined Executive. Executive hereby
consents to such examination and consultation regarding Executive’s health and ability to perform as aforesaid.

 

    	2

    	 

    

 

(d)              
Definition of “Cause”. As used herein, “Cause” shall include: (i) Executive’s
willful engagement in dishonesty, illegal conduct or gross misconduct, which is, in each case, injurious to Company; (ii) Executive’s
substantial malfeasance or nonfeasance of duty; (iii) Executive’s unauthorized disclosure of confidential information; (iv)
Executive’s embezzlement, misappropriation or fraud, whether or not related Executive’s employment with Company; or
(v) Executive’s breach of a material provision of any employment, non-disclosure, invention assignment, non-competition,
or similar agreement between Executive and Company. “Cause” is not limited to events which have occurred prior to the
termination of Executive’s service, nor is it necessary that the Board’s finding of “Cause” occur prior
to such termination. If the Board determines, subsequent to Executive’s termination of service, that either prior or subsequent
to Executive’s termination Executive engaged in conduct which would constitute “Cause,” then Executive shall
have no right to any benefit or compensation under this Agreement. Notwithstanding the foregoing, the events or acts described
in (ii), (iii) and (v) above will not constitute “Cause” if such events or acts, if curable, are cured by the Executive
within fifteen (15) days after delivery of written notice by the Company to Executive thereof.

 

(e)               
Definition of “Good Reason”. As used herein, “Good Reason” shall mean: (i) relocation
of Executive’s principal business location to a location more than fifty (50) miles from Executive’s then-current business
location; (ii) a material diminution in Executive’s duties, authority or responsibilities; or (iii) a material reduction
in Executive’s Base Salary; provided that (A) Executive provides Company with written notice that Executive intends
to terminate Executive’s employment hereunder for one of the circumstances set forth in this Section 2(e) within thirty (30)
days of such circumstance occurring, (B) if such circumstance is capable of being cured, Company has failed to cure such circumstance
within a period of thirty (30) days from the date of such written notice, and (C) Executive terminates Executive’s employment
within sixty (60) days from the date that Good Reason first occurs. For purposes of clarification, the above-listed conditions
shall apply separately to each occurrence of Good Reason and failure to adhere to such conditions in the event of Good Reason shall
not disqualify Executive from asserting Good Reason for any subsequent occurrence of Good Reason. For purposes of this Agreement,
“Good Reason” shall be interpreted in a manner, and limited to the extent necessary, so that it shall not cause adverse
tax consequences for either party with respect to Section 409A (“Section 409A”) of the Internal Revenue Code of 1986,
as amended (the “Code”), and any successor statute, regulation and guidance thereto.

 

3.                 
Compensation.

 

(a)               
Base Salary. Company shall pay Executive a base salary (the “Base Salary”) at the annual rate
of three hundred sixty five thousand dollars ($365,000). The Base Salary shall be payable in substantially equal periodic installments
in accordance with Company’s payroll practices as in effect from time to time. Company shall deduct from each such installment
all amounts required to be deducted or withheld under applicable law or under any employee benefit plan in which Executive participates.
The Board or an appropriate committee thereof shall review the Base Salary on an annual basis, and may increase (but not decrease)
the Base Salary based on such review.

 

(b)              
Annual Performance Bonus. Subject to the terms of the applicable Company bonus plan, Executive shall be eligible
to receive an annual cash bonus, including an annual stretch bonus opportunity (the “Annual Performance Bonus”). The
target amount of such Annual Performance Bonus shall be equal to thirty five percent (35%) of Executive’s Base Salary, with
a stretch bonus opportunity equal to 1.5 times the Executive’s applicable target bonus opportunity; provided that
any Annual Performance Bonus for calendar year 2015 shall be made on a pro rata basis to account for the timing of the Commencement
Date (and the period of time worked thereafter) in calendar year 2015, and further provided that the actual amount of the
Annual Performance Bonus for calendar year 2015 and for any successive calendar year of employment hereunder may be greater or
less than the applicable target amount. The actual amount of the Annual Performance Bonus shall be determined by the Board or an
appropriate committee thereof in its sole discretion, and shall be paid to Executive no later than March 15th of the
calendar year immediately following the calendar year in which it was earned. Executive must be employed by Company through December
31st of the applicable calendar year in order to be eligible for, and to be deemed as having earned, such Annual Performance
Bonus. Company shall deduct from the Annual Performance Bonus all amounts required to be deducted or withheld under applicable
law or under any employee benefit plan in which Executive participates. Company and Executive will negotiate in good faith to establish
Company and/or individual performance criteria pursuant to which Executive will be eligible to earn an Annual Performance Bonus
for each calendar year by January 31st of such year; provided that Company and Executive will negotiate in good
faith to establish the performance criteria for calendar year 2015 no later than thirty (30) days following the Commencement Date.

 

    	3

    	 

    

 

(c)               
Equity. Subject to approval of the Board or an appropriate committee thereof, Company shall grant Executive
on the Commencement Date or as soon as practicable thereafter:

 

(i)                
Options to purchase 14,245,227 shares of common stock of Company (the “Initial Option”), at a per share
exercise price equal to the Fair Market Value (as defined in the Company’s 2013 Employee, Director and Consultant Equity
Incentive Plan (the “Plan”), of Company’s common stock on the date of grant, which options shall be, to the maximum
extent permissible under law (and to the extent such shares are reserved for issuance under the Plan), treated as “incentive
stock options” within the meaning of Section 422 of the Code. Twenty five percent (25%) of the shares subject to the Initial
Option shall vest on the first (1st) anniversary of the Commencement Date, and 2.083% of the shares subject to the Initial
Option shall vest on the last day of each successive month thereafter, provided that Executive remains employed by Company
on the vesting date, except as otherwise set forth herein or in the Plan.

 

(ii)              
In addition, in the event that Company consummates a “Qualified
Financing” (as defined below) within eighteen (18) months following the Commencement Date, then Company shall grant Executive
additional options (the “Supplemental Option”) to purchase an amount of shares of common stock of Company equal to
five percent (5%) of the number of shares of Company common stock issued in such Qualified Financing (assuming the conversion of
all convertible securities issued in such Qualified Financing) at a per share exercise price equal to the Fair Market Value (as
defined in the Plan) of Company’s common stock on the date of grant, which options shall be, to the maximum extent permissible
under law (and to the extent such shares are reserved for issuance under the Plan), treated as “incentive stock options”
within the meaning of Section 422 of the Code. Twenty five percent (25%) of the shares subject to the Supplemental Option shall
vest on the first (1st) anniversary of the date of grant, and 2.083% of the shares subject to the Supplemental Option
shall vest on the last day of each successive month thereafter, provided that Executive remains employed by Company on the
vesting date, except as otherwise set forth herein or in the Plan. For the purposes of this paragraph, the term “Qualified
Financing” shall mean the consummation of a financing transaction or series of related equity financings pursuant to which
the aggregate gross proceeds received by Company from investors is no less than five million dollars ($5,000,000).

 

    	4

    	 

    

 

Following
Executive’s termination from employment for any reason (other than a termination by Company for Cause), the post-termination
exercise period applicable to the Initial Option and the Supplemental Option will be the earlier of (i) the expiration date of
the applicable option award as set forth in the applicable equity agreement and/or the Plan, or (ii) twelve (12) months following
the termination date.

 

The Initial
Option and the Supplemental Option, as applicable, shall be evidenced in writing by, and subject to the terms and conditions of,
the Plan and/or a stock option agreement, which agreement shall expire ten (10) years from the date of grant except as otherwise
provided in the stock option agreement or the Plan, as applicable.

 

(d)              
Paid Time Off. Executive may take up to twenty (20) days of paid time off (“PTO”) per year, to
be scheduled to minimize disruption to Company’s operations, pursuant to the terms and conditions of Company policy and practices
as applied to Company senior executives.

 

(e)               
Fringe Benefits. Executive shall be entitled to participate in all benefit/welfare plans and fringe benefits
provided to Company senior executives. Executive understands that, except when prohibited by applicable law, Company’s benefit
plans and fringe benefits may be amended by Company from time to time in its sole discretion.

 

(f)               
Reimbursement of Expenses. Company shall reimburse Executive for all ordinary and reasonable out-of-pocket
business expenses incurred by Executive in furtherance of Company’s business in accordance with Company’s policies
with respect thereto as in effect from time to time. Executive must submit any request for reimbursement no later than ninety (90)
days following the date that such business expense is incurred. All reimbursements provided under this Agreement shall be made
or provided in accordance with the requirements of Section 409A including, where applicable, the requirement that (i) any reimbursement
is for expenses incurred during Executive’s lifetime (or during a shorter period of time specified in this Agreement); (ii)
the amount of expenses eligible for reimbursement during a calendar year may not affect the expenses eligible for reimbursement
in any other calendar year; (iii) the reimbursement of an eligible expense shall be made no later than the last day of the calendar
year following the year in which the expense is incurred; and (iv) the right to reimbursement or in kind benefits is not subject
to liquidation or exchange for another benefit.

 

(g)               
Legal Fees. Company shall reimburse Executive up to five thousand dollars ($5,000) for reasonable and actual
legal expenses incurred by Executive in connection with the negotiation, preparation and execution of this Agreement, upon presentation
of documentation supporting same (i.e., redacted invoices) and subject to the terms and conditions of Section 3(f) and Company
policy.

 

4.                 
Payments Upon Termination.

 

(a)               
Definition of Accrued Obligations. For purposes of this Agreement, “Accrued Obligations” means:
(i) the portion of Executive’s Base Salary that has accrued prior to any termination of Executive’s employment with
Company and has not yet been paid; and (ii) the amount of any expenses properly incurred by Executive on behalf of Company prior
to any such termination and not yet reimbursed. Executive’s entitlement to any other compensation or benefit under any plan
of Company shall be governed by and determined in accordance with the terms of such plans, except as otherwise specified in this
Agreement.

 

    	5

    	 

    

 

(b)              
Termination by Company for Cause, by Executive Without Good Reason, or as a Result of Executive’s Disability
or Death. If Executive’s employment hereunder is terminated by Company for Cause, by Executive without Good Reason, or
as a result of Executive’s Disability or death, then Company shall pay the Accrued Obligations to Executive promptly following
the effective date of such termination and shall have no further obligations to Executive.

 

(c)               
Termination by Company Without Cause or by Executive For Good Reason. In the event that Executive’s
employment is terminated by action of Company other than for Cause, or Executive terminates Executive’s employment for Good
Reason, then, in addition to the Accrued Obligations, Executive shall receive the following, subject to the terms and conditions
described in Section 4(e) (including Executive’s execution of a release of claims):

 

(i)                
Severance Payments. Continuation of payments in an amount equal to Executive’s then-current Base Salary
for a twelve (12) month period, less all customary and required taxes and employment-related deductions, in accordance with Company’s
normal payroll practices (provided such payments shall be made at least monthly), commencing on the first payroll date following
the date on which the release of claims required by Section 4(e) becomes effective and non-revocable; but not after seventy (70)
days following the effective date of termination from employment; provided that if the 70th day falls in the
calendar year following the year during which the termination or separation from service occurred, then the payments will commence
in such subsequent calendar year; provided further that if such payments commence in such subsequent year, the first such
payment shall be a lump sum in an amount equal to the payments that would have come due since Employee’s separation from
service.

 

(ii)              
Benefits Payments. Upon completion of appropriate forms and subject to applicable terms and conditions under
the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (“COBRA”), Company shall continue to provide
Executive medical insurance coverage at no cost to Executive to the same extent that such insurance continues to be provided to
similarly situated executives at the time of Executive’s termination, until the earlier to occur of: (A) twelve (12) months
following Executive’s termination date, or (B) the date Executive begins employment with another employer. Executive shall
bear full responsibility for applying for COBRA continuation coverage and Company shall have no obligation to provide Executive
such coverage if Executive fails to elect COBRA benefits in a timely fashion.

 

Payment of the above
described severance payments and benefits are expressly conditioned on Executive’s execution without revocation of the release
of claims under Section 4(e) and return of Company property under Section 6. In the event that Executive is eligible for the severance
payments and benefits under this Section 4(c), Executive shall not be eligible for and shall not receive any of the severance payments
and benefits as provided in Section 4(d).

 

(d)              
Termination by Company Without Cause or by Executive For Good Reason Following a Change of Control. In the
event that a Change of Control (as defined below) occurs and within a period of one (1) year following the Change of Control, either
Executive’s employment is terminated by Company other than for Cause, or Executive terminates Executive’s employment
for Good Reason, then, in addition to the Accrued Obligations, Executive shall receive the following, subject to the terms and
conditions described in Section 4(e) (including Executive’s execution of a release of claims):

 

    	6

    	 

    

 

(i)                
Lump Sum Severance Payment. Payment of a lump sum amount equal to twelve (12) months of Executive’s
then-current Base Salary, less all customary and required taxes and employment-related deductions, paid on the first payroll date
following the date on which the release of claims required by Paragraph 4(e) becomes effective and non-revocable, but not after
seventy (70) days following the effective date of termination from employment.

 

(ii)              
Benefit Payments. Upon completion of appropriate forms and subject to applicable terms and conditions under
COBRA, Company shall continue to provide Executive medical insurance coverage at no cost to Executive to the same extent that such
insurance continues to be provided to similarly situated executives at the time of Executive’s termination, until the earlier
to occur of: (A) twelve (12) months following Executive’s termination date, or (B) the date Executive begins employment with
another employer. Executive shall bear full responsibility for applying for COBRA continuation coverage and Company shall have
no obligation to provide Executive such coverage if Executive fails to elect COBRA benefits in a timely fashion.

 

(iii)            
Equity Acceleration. On the date of termination of Executive’s employment, Executive shall become fully
vested in any and all equity awards outstanding as of the date of Executive’s termination. Please note that the acceleration
of vesting of options and/or the extension of exercise periods applicable to same may cause certain options currently deemed to
be incentive share options taxable in accordance with Section 422 of the Code to be converted into non-qualified share options,
which are taxable upon exercise. Executive acknowledges and agrees that Company does not guarantee or make any representations
regarding the tax consequences of this provision or the tax treatment of any equity awards.

 

Payment of the above
described severance payments and benefits are expressly conditioned on Executive’s execution without revocation of the release
of claims under Section 4(e) and return of Company property under Section 6. In the event that Executive is eligible for the severance
payments and benefits under this Section 4(d), Executive shall not be eligible for and shall not receive any of the severance payments
and benefits as provided in Section 4(c).

 

As used herein, a “Change
of Control” shall mean the occurrence of any of the following events: (i) Ownership. Any “Person” (as
such term is used in Sections 13(d) and 14(d) of the Securities Exchange Act of 1934, as amended) becomes the “Beneficial
Owner” (as defined in Rule 13d-3 under said Act), directly or indirectly, of securities of Company representing fifty percent
(50%) or more of the total voting power represented by Company’s then outstanding voting securities (excluding for this purpose
any such voting securities held by Company, or any affiliate, parent or subsidiary of Company, or by any employee benefit plan
of Company) pursuant to a transaction or a series of related transactions which the Board does not approve; or (ii) Merger/Sale
of Assets. (A) A merger or consolidation of Company whether or not approved by the Board, other than a merger or consolidation
which would result in the voting securities of Company outstanding immediately prior thereto continuing to represent (either by
remaining outstanding or by being converted into voting securities of the surviving entity or the parent of such corporation) at
least fifty percent (50%) of the total voting power represented by the voting securities of Company or such surviving entity or
parent of such corporation, as the case may be, outstanding immediately after such merger or consolidation; (B) or Company’s
stockholders approve an agreement for the sale or disposition by Company of all or substantially all of Company’s assets;
or (iii) Change in Board Composition. A change in the composition of the Board, as a result of which fewer than a majority
of the directors are Incumbent Directors. “Incumbent Directors” shall mean directors who either (A) are directors of
Company as of the date of this Agreement, or (B) are elected, or nominated for election, to the Board with the affirmative votes
of at least a majority of the Incumbent Directors, or by a committee of the Board made up of at least a majority of the Incumbent
Directors, at the time of such election or nomination (but shall not include an individual whose election or nomination is in connection
with an actual or threatened proxy contest relating to the election of directors).

 

    	7

    	 

    

 

(e)               
Execution of Release of Claims. Company shall not be obligated to pay Executive any of the severance payments
or benefits described in this Section 4 unless and until Executive has executed (without revocation) a timely release of claims
in a form that is acceptable to Company, and which includes standard and reasonable terms regarding items such as mutual non-disparagement,
confidentiality, cooperation and the like, which must be provided to Executive within fifteen (15) days following separation from
service, and signed by Executive and returned to Company no later than sixty (60) days following Executive’s separation from
service (the “Review Period”), and which shall include a general release of claims against Company and its affiliated
entities and each of their officers, directors, employees and others associated with Company and its affiliated entities. If Executive
fails or refuses to return such agreement within the Review Period, Executive’s severance payments hereunder and benefits
shall be forfeited.

 

(f)               
No Other Payments or Benefits Owing. The payments and benefits set forth in this Section 4 shall be the sole
amounts owing to Executive upon termination of Executive’s employment for the reasons set forth above and Executive shall
not be eligible for any other payments or other forms of compensation or benefits. The payments and benefits set forth in Section
4 shall be the sole remedy, if any, available to Executive in the event that Executive brings any claim against Company relating
to the termination of Executive’s employment under this Agreement.

 

(g)               COBRA.
If the payment of any COBRA or health insurance premiums by Company on behalf of Executive as described herein would
otherwise violate any applicable nondiscrimination rules or cause the reimbursement of claims to be taxable under the Patient
Protection and Affordable Care Act of 2010, together with the Health Care and Education Reconciliation Act of 2010
(collectively, the “Act”) or Section 105(h) of the Code, the COBRA premiums paid by Company shall be treated as
taxable payments (subject to customary and required taxes and employment-related deductions) and be subject to imputed income
tax treatment to the extent necessary to eliminate any discriminatory treatment or taxation under the Act or Section 105(h)
of the Code. If Company determines in its sole discretion that it cannot provide the COBRA benefits described herein under
Company’s health insurance plan without potentially violating applicable law (including, without limitation, Section
2716 of the Public Health Service Act), Company shall in lieu thereof provide to Executive a taxable lump-sum payment in an
amount equal to the sum of the monthly (or then remaining) COBRA premiums that Executive would be required to pay to maintain
Executive’s group health insurance coverage in effect on the separation date for the remaining portion of the period
for which Executive shall receive the payments described in Section 4.

 

5.                 
Prohibited Competition and Solicitation. Executive expressly acknowledges that: (a) there are competitive
and proprietary aspects of the business of Company; (b) during the course of Executive’s employment, Company shall furnish,
disclose or make available to Executive confidential and proprietary information and may provide Executive with unique and specialized
training; (c) such Confidential Information and training have been developed and shall be developed by Company through the expenditure
of substantial time, effort and money, and could be used by Executive to compete with Company; and (d) in the course of Executive’s
employment, Executive shall be introduced to customers and others with important relationships to Company, and any and all “goodwill”
created through such introductions belongs exclusively to Company, including, but not limited to, any goodwill created as a result
of direct or indirect contacts or relationships between Executive and any customers of Company. In light of the foregoing acknowledgements,
and as a condition of employment hereunder, Executive agrees to execute and abide by Company’s Non-Competition, Non-Solicitation,
Confidentiality and Assignment of Inventions Agreement.

 

    	8

    	 

    

 

6.                 
Property and Records. Upon the termination of Executive’s employment hereunder for any reason or
for no reason, or if Company otherwise requests, Executive shall: (a) return to Company all tangible business information and copies
thereof (regardless how such Confidential Information or copies are maintained), and (b) deliver to Company any property of Company
which may be in Executive’s possession, including, but not limited to, Blackberry-type devices, smart phones, laptops, cell
phones, products, materials, memoranda, notes, records, reports or other documents or photocopies of the same.

 

7.                 
Indemnification. Executive shall be entitled to indemnification with respect to Executive’s services
provided hereunder pursuant to Delaware law, the terms and conditions of Company’s certificate of incorporation and/or by-laws,
Company’s directors and officers (“D&O”) liability insurance policy, and Company’s standard indemnification
agreement for directors as executed by Company and Executive.

 

8.                 
Code Sections 409A and 280G. 

 

(a)               
In the event that the payments or benefits set forth in Section 4 of this Agreement constitute “non-qualified
deferred compensation” subject to Section 409A, then the following conditions apply to such payments or benefits:

 

(i)                
Any termination of Executive’s employment triggering payment of benefits under Section 4 must constitute a
“separation from service” under Section 409A(a)(2)(A)(i) of the Code and Treas. Reg. §1.409A-1(h) before distribution
of such benefits can commence. To the extent that the termination of Executive’s employment does not constitute a separation
of service under Section 409A(a)(2)(A)(i) of the Code and Treas. Reg. §1.409A-1(h) (as the result of further services that
are reasonably anticipated to be provided by Executive to Company at the time Executive’s employment terminates), any such
payments under Section 4 that constitute deferred compensation under Section 409A shall be delayed until after the date of a subsequent
event constituting a separation of service under Section 409A(a)(2)(A)(i) of the Code and Treas. Reg. §1.409A-1(h). For purposes
of clarification, this Section 8 shall not cause any forfeiture of benefits on Executive’s part, but shall only act as a
delay until such time as a “separation from service” occurs.

 

(ii)              
Notwithstanding any other provision with respect to the timing of payments under Section 4 if, at the time of Executive’s
termination, Executive is deemed to be a “specified employee” of Company (within the meaning of Section 409A(a)(2)(B)(i)
of the Code), then limited only to the extent necessary to comply with the requirements of Section 409A, any payments to which
Executive may become entitled under Section 4 which are subject to Section 409A (and not otherwise exempt from its application)
shall be withheld until the first (1st) business day of the seventh (7th) month following the termination
of Executive’s employment, at which time Executive shall be paid an aggregate amount equal to the accumulated, but unpaid,
payments otherwise due to Executive under the terms of Section 4.

 

    	9

    	 

    

 

(b)              
It is intended that each installment of the payments and benefits provided under Section 4 of this Agreement shall
be treated as a separate “payment” for purposes of Section 409A. Neither Company nor Executive shall have the right
to accelerate or defer the delivery of any such payments or benefits except to the extent specifically permitted or required by
Section 409A.

 

(c)               
Notwithstanding any other provision of this Agreement to the contrary, this Agreement shall be interpreted and at
all times administered in a manner that avoids the inclusion of compensation in income under Section 409A, or the payment of increased
taxes, excise taxes or other penalties under Section 409A. The parties intend this Agreement to be in compliance with Section 409A.
Executive acknowledges and agrees that Company does not guarantee the tax treatment or tax consequences associated with any payment
or benefit arising under this Agreement, including but not limited to consequences related to Section 409A.

 

(d)              
If any payment or benefit Executive would receive under this Agreement, when combined with any other payment or benefit
Executive receives pursuant to a Change of Control (for purposes of this section, a “Payment”) would: (i) constitute
a “parachute payment” within the meaning of Section 280G the Code; and (ii) but for this sentence, be subject to the
excise tax imposed by Section 4999 of the Code (the “Excise Tax”), then such Payment shall be either: (A) the full
amount of such Payment; or (B) such lesser amount (with cash payments being reduced before stock option compensation) as would
result in no portion of the Payment being subject to the Excise Tax, whichever of the foregoing amounts, taking into account the
applicable federal, state and local employments taxes, income taxes, and the Excise Tax, results in Executive’s receipt,
on an after-tax basis, of the greater amount of the Payment notwithstanding that all or some portion of the Payment may be subject
to the Excise Tax.

 

9.                 
General.

 

(a)               
Notices. Except as otherwise specifically provided herein, any notice required or permitted by this Agreement
shall be in writing and shall be delivered as follows with notice deemed given as indicated: (i) by personal delivery when delivered
personally; (ii) by overnight courier upon written verification of receipt; (iii) by telecopy or facsimile transmission upon acknowledgment
of receipt of electronic transmission; or (iv) by certified or registered mail, return receipt requested, upon verification of
receipt.

 

Notices to Executive
shall be sent to the last known address in Company’s records or such other address as Executive may specify in writing. 

 

Notices to Company
shall be sent to: 

 

Interleukin Genetics,
Inc.

135 Beaver Street

Waltham, MA 02452

Attn: Chairman

 

or to such other
Company representative as Company may specify in writing, with a copy to:

 

Mintz, Levin, Cohn,
Ferris, Glovsky and Popeo, P.C.

One Financial Center

Boston, MA 02111

Attn: Brian P. Keane,
Esq.

 

    	10

    	 

    

 

(b)              
Modifications and Amendments. The terms and provisions of this Agreement may be modified or amended only by
written agreement executed by the parties hereto.

 

(c)               
Waivers and Consents. The terms and provisions of this Agreement may be waived, or consent for the departure
therefrom granted, only by written document executed by the party entitled to the benefits of such terms or provisions. No such
waiver or consent shall be deemed to be or shall constitute a waiver or consent with respect to any other terms or provisions of
this Agreement, whether or not similar. Each such waiver or consent shall be effective only in the specific instance and for the
purpose for which it was given, and shall not constitute a continuing waiver or consent.

 

(d)              
Assignment. Company may assign its rights and obligations hereunder to any person or entity that succeeds
to all or substantially all of Company’s business or that aspect of Company’s business in which Executive is principally
involved. Executive may not assign Executive’s rights and obligations under this Agreement without the prior written consent
of Company.

 

(e)               
Governing Law/Dispute Resolution. This Agreement and the rights and obligations of the parties hereunder shall
be construed in accordance with and governed by the law of Massachusetts, without giving effect to the conflict of law principles
thereof. Any legal action or proceeding with respect to this Agreement shall be brought in the courts of Massachusetts or of the
United States of America for the District of Massachusetts. By execution and delivery of this Agreement, each of the parties hereto
accepts for itself and in respect of its property, generally and unconditionally, the non-exclusive jurisdiction of the aforesaid
courts.

 

(f)               
Jury Waiver. ANY, ACTION, DEMAND, CLAIM, OR COUNTERCLAIM ARISING UNDER OR RELATING TO THIS AGREEMENT SHALL
BE RESOLVED BY A JUDGE ALONE AND EACH OF COMPANY AND EXECUTIVE WAIVES ANY RIGHT TO A JURY TRIAL THEREOF.

 

(g)               
Headings and Captions. The headings and captions of the various subdivisions of this Agreement are for convenience
of reference only and shall in no way modify or affect the meaning or construction of any of the terms or provisions hereof.

 

(h)              
Entire Agreement. This Agreement, together with the other agreements specifically referenced herein, embodies
the entire agreement and understanding between the parties hereto with respect to the subject matter hereof and supersedes all
prior oral or written agreements and understandings relating to the subject matter hereof. No statement, representation, warranty,
covenant or agreement of any kind not expressly set forth in this Agreement shall affect, or be used to interpret, change or restrict,
the express terms and provisions of this Agreement.

 

(i)                
Counterparts. This Agreement may be executed in two or more counterparts, and by different parties hereto
on separate counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same
instrument. For all purposes a signature by fax shall be treated as an original.

 

    	11

    	 

    

 

[Signature Page to Follow]

 

    	12

    	 

    

 

IN WITNESS WHEREOF,
the parties hereto have executed this Agreement as of the date first written above.

 

	MARK CARBEAU	 	INTERLEUKIN GENETICS, INC.	 
	 	 	 	 	 
	/s/ Mark B. Carbeau	 	By: 	   /s/ James M. Weaver	 
	Signature	 	 	Name: James M. Weaver	 
	 	 	 	Title: Chairman	 

  

    	 

    	 

    

  

EXHIBIT A

 

		·	Diagnostyx, Inc. Director, 10 Corey Street, Melrose, MA (Drug infusion
systems and remote monitoring)

		·	Penn State University, Industrial and Professional Advisory Council
(IPAC) Board (Advisory to Dean, College of Engineering)

 

    	14

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00243-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00243-of-00352.parquet"}]]